Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) dropped 5.2% on Tuesday after an insider sold shares in the company. The company traded as low as $7.59 and last traded at $7.69. Approximately 1,900,358 shares traded hands during mid-day trading, an increase of 135% from the average daily volume of 809,404 shares. The stock had previously closed at $8.11.
Specifically, insider Thomas R. Staab II sold 7,500 shares of BioCryst Pharmaceuticals stock in a transaction on Thursday, April 4th. The stock was sold at an average price of $8.81, for a total transaction of $66,075.00. Following the completion of the sale, the insider now directly owns 140,176 shares of the company’s stock, valued at $1,234,950.56. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CFO Thomas R. Staab II sold 7,750 shares of BioCryst Pharmaceuticals stock in a transaction on Thursday, May 2nd. The stock was sold at an average price of $7.30, for a total value of $56,575.00. Following the sale, the chief financial officer now directly owns 140,426 shares of the company’s stock, valued at $1,025,109.80. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 24,250 shares of company stock valued at $192,400. 5.20% of the stock is owned by insiders.
BCRX has been the subject of a number of analyst reports. Zacks Investment Research raised BioCryst Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, March 26th. BidaskClub cut BioCryst Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Thursday, January 31st. Piper Jaffray Companies set a $15.00 price objective on BioCryst Pharmaceuticals and gave the stock a “buy” rating in a research note on Monday, April 22nd. Barclays lifted their price objective on BioCryst Pharmaceuticals from $6.00 to $8.00 and gave the stock an “equal weight” rating in a research note on Tuesday, April 2nd. Finally, JMP Securities lifted their price objective on BioCryst Pharmaceuticals from $16.00 to $18.00 and gave the stock a “market outperform” rating in a research note on Tuesday, April 2nd. Five investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average price target of $11.91.
The company has a quick ratio of 1.62, a current ratio of 1.65 and a debt-to-equity ratio of 0.57. The company has a market cap of $861.21 million, a PE ratio of -7.97 and a beta of 1.71.
BioCryst Pharmaceuticals (NASDAQ:BCRX) last posted its earnings results on Wednesday, May 8th. The biotechnology company reported ($0.28) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.28). BioCryst Pharmaceuticals had a negative return on equity of 175.83% and a negative net margin of 490.25%. As a group, equities research analysts anticipate that BioCryst Pharmaceuticals, Inc. will post -1.2 EPS for the current fiscal year.
Large investors have recently bought and sold shares of the business. Paloma Partners Management Co acquired a new position in BioCryst Pharmaceuticals in the fourth quarter valued at about $84,000. Great West Life Assurance Co. Can grew its stake in BioCryst Pharmaceuticals by 82.7% in the first quarter. Great West Life Assurance Co. Can now owns 13,336 shares of the biotechnology company’s stock valued at $108,000 after acquiring an additional 6,036 shares during the period. Amalgamated Bank acquired a new position in BioCryst Pharmaceuticals in the fourth quarter valued at about $122,000. Legal & General Group Plc grew its stake in BioCryst Pharmaceuticals by 14.5% in the fourth quarter. Legal & General Group Plc now owns 19,315 shares of the biotechnology company’s stock valued at $156,000 after acquiring an additional 2,453 shares during the period. Finally, SG Americas Securities LLC acquired a new position in BioCryst Pharmaceuticals in the first quarter valued at about $169,000. 91.81% of the stock is owned by hedge funds and other institutional investors.
ILLEGAL ACTIVITY WARNING: This news story was reported by Equities Focus and is the property of of Equities Focus. If you are accessing this news story on another publication, it was illegally copied and republished in violation of United States and international trademark and copyright laws. The legal version of this news story can be viewed at https://www.equitiesfocus.com/2019/05/09/biocryst-pharmaceuticals-bcrx-shares-down-5-2-on-insider-selling.html.
BioCryst Pharmaceuticals Company Profile (NASDAQ:BCRX)
BioCryst Pharmaceuticals, Inc, a biotechnology company, discovers oral and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor, for the treatment of acute uncomplicated influenza under the RAPIVAB, ALPIVAB, RAPIACTA, and PERAMIFLU names; and Mundesine, an oral purine nucleoside phosphorylase inhibitor for peripheral T-cell lymphoma.
Read More: Fibonacci Channel
Receive News & Ratings for BioCryst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.